ABSTRACT
Purpose/Objectives Despite advances in cancer genomics, radiation therapy (RT) is still prescribed based on an empiric one-size-fits-all paradigm. Previously, we proposed a novel algorithm using the genomic adjusted radiation dose (GARD) to personalize RT prescription dose based on the biological effect of a given physical dose, calculated using individual tumor genomics. To validate the GARD-based RT dosing paradigm, we performed a pooled pan-cancer analysis in 9 separate clinical cohorts.
Materials/Methods We collected 9 previously-published datasets for which all information to calculate GARD was available. Two clinical endpoints were defined: 1. time to any recurrence and 2. overall survival. The recurrence and survival analysis, included a total of 1098 (895 +RT, 203 -RT) and 821 patients (517 +RT, 304 -RT), respectively. A stratified Cox proportional hazard regression analysis was performed. A model was constructed in each disease site using GARD as the covariate and a common GARD effect was estimated.
Results GARD is a continuous pan-cancer predictor of both recurrence and overall survival in patients treated with RT (any recurrence: coefficient =-0.019, χ-square=8.9, p =0.003; overall survival: coefficient =-0.015, χ-square=4.5, p =0.034), and was not predictive in those not treated with RT (any recurrence: coefficient =-0.033, χ-square=1.3, p =0.247; overall survival: coefficient =0.016, χ-square=2.1, p =0.148).
Conclusions GARD is significantly associated with recurrence and survival in a continuous manner for the subset of patients receiving RT. We propose that a GARD-based framework should be adopted as the new paradigm for personalizing RT dose.
Competing Interest Statement
JGS, SAE and JFTR hold IP on RSI, GARD and RxRSI, in addition to equity in Cvergenx, a company which seeks to commercialize these methods.
Funding Statement
No funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a retrospective analysis of published data, information on IRB approvals are contained in cited publications.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are published previously in this pooled analysis. The code (and data) are available on github.